华泰联合证券有限责任公司 关于广东众生药业股份有限公司 变更部分募集资金用途的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为广 东众生药业股份有限公司（以下简称"众生药业"或"公司"、"上市公司"）2022 年向特定对象发行股票并在主板上市的保荐机构，根据《深圳证券交易所股票上市 规则》《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《深 圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关法 律法规和规范性文件的规定，对公司变更部分募集资金用途事项进行了审慎尽职调 查，具体核查情况如下： 一、变更募集资金投资项目的概述 （一）募集资金基本情况 | 序 | 项目名称 | 投资总额 | 拟使用募集 | 实际募集资 | 截至 2025 年 6 | 月 | 未使用募集资 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | 资金金额 | 金净额 | 4 日累计投入金额 | | 金金额 | | 1 | 中药提取车间 | 30,105.00 | 18,100.00 | 18,100.0 ...

证券代码：002317 公告编号：2025-058 广东众生药业股份有限公司 关于变更部分募集资金用途的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 6 月 6 日召开了 第八届董事会第二十二次会议和第八届监事会第二十二次会议，审议通过了《关 于变更部分募集资金用途的议案》，同意将"抗肿瘤药研发项目"剩余未使用募 集资金 4,325.78 万元及专户利息 792.68 万元和"数字化平台升级建设项目"剩 余未使用募集资金 4,933.15 万元及专户利息 255.93 万元（上述专户利息均截止 至 2025 年 6 月 4 日），共计 10,307.54 万元，变更用于公司控股子公司广东众生 睿创生物科技有限公司（以下简称"众生睿创"）"新药研发项目"（本次变更募 投项目实际金额以资金转出当日专户的募集资金余额为准）。 根据《深圳证券交易所股票上市规则》《上市公司监管指引第 2 号——上市 公司募集资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范 ...

证券代码：002317 公告编号：2025-059 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十 二次会议决议，公司决定于 2025 年 6 月 23 日召开公司 2025 年第二次临时股东 大会。现将有关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次：2025 年第二次临时股东大会 （二）会议召集人：本次股东大会由公司董事会召集。本次股东大会的召开 已经公司第八届董事会第二十二次会议审议通过。 （三）会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政 法规、部门规章、规范性文件、深圳证券交易所(以下简称"深交所")业务规则 和《公司章程》的规定。 （四）会议召开的日期、时间： 1、现场会议时间：2025 年 6 月 23 日下午 2:45 开始 2、网络投票时间： 广东众生药业股份有限公司 （1）通过深交所交易系统进行网络投票的具体时间为 2025 年 6 月 23 日 9:15～9:25，9:30～11:30 和 13 ...

经与会监事签名的监事会决议。 证券代码：002317 公告编号：2025-057 一、审议通过了《关于变更部分募集资金用途的议案》。 经审核，监事会认为董事会审议本次变更部分募集资金的用途的议案程序符 合中国证监会和深圳证券交易所的相关规定，审议和表决的结果合法有效。本次 变更是公司依据市场环境变化等因素做出的决策，有利于提高募集资金使用效率， 维护全体股东利益和满足公司长期发展需要，不存在损害公司和股东利益的情形。 表决结果：3 票同意，0 票反对，0 票弃权。 备查文件 广东众生药业股份有限公司 第八届监事会第二十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届监事会第二十二次 会议的会议通知于 2025 年 5 月 30 日以专人和电子邮件方式送达全体监事，会议 于 2025 年 6 月 6 日在公司会议室以现场表决方式召开。本次会议应出席监事 3 人，实际出席监事 3 人，会议由公司监事会主席谭珍友先生主持，董事会秘书列 席本次会议。本次会议的召集和召开符合法律、法规和《公司章程》的有 ...

一、审议通过了《关于变更部分募集资金用途的议案》。本议案尚需提交公 司 2025 年第二次临时股东大会审议。 证券代码：002317 公告编号：2025-056 广东众生药业股份有限公司 第八届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十二次 会议的会议通知于 2025 年 5 月 30 日以专人和电子邮件方式送达全体董事，会议 于 2025 年 6 月 6 日在公司会议室以现场和通讯表决方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监事、 董事会秘书列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的 有关规定。经与会董事认真审议，以记名投票方式表决，做出如下决议： 公司基于整体战略布局及经营发展的需要，为了更科学、审慎、有效地使用 募集资金，同意将"抗肿瘤药研发项目"剩余未使用募集资金 4,325.78 万元及专 户利息 792.68 万元和"数字化平台升级建设项目"剩余未使用募集资金 4,933.15 ...

Group 1 - The A-share innovative drug concept has experienced a volatile rebound, with Changshan Pharmaceutical rising over 16% to reach a historical high [1] - Lianhua Technology increased by more than 9%, indicating positive market sentiment towards innovative drug companies [1] - Other companies such as Anglikang, Sailun Bio, Wanbangde, and Zhongsheng Pharmaceutical also saw gains, reflecting a broader trend in the sector [1]

Core Viewpoint - The article discusses the successful development and market entry of the innovative flu drug, Olanidavir, by Zhongsheng Pharmaceutical, which has managed to outperform the established flu medication, Oseltamivir, in clinical trials [3][4][7]. Industry Progress - Since the initiation of drug regulation reforms in 2015, China's biopharmaceutical industry has made significant advancements in drug development, achieving breakthroughs in several areas previously dominated by multinational companies [3]. - The emergence of valuable drug molecules from both new and established pharmaceutical companies is expected to create substantial economic and social value for China [3]. Company Development - Zhongsheng Pharmaceutical's Olanidavir is the first flu RNA polymerase PB2 protein inhibitor approved in China, marking a significant milestone in the company's innovation journey [4][17]. - The drug was developed over a decade, with a focus on addressing the limitations of existing treatments, particularly the resistance and side effects associated with Oseltamivir [6][19]. Clinical Trial Success - In head-to-head clinical trials, Olanidavir demonstrated a median symptom relief time and fever relief time shorter than that of Oseltamivir, with nearly a 10% reduction in illness duration [7]. - Olanidavir showed superior efficacy against flu viruses, including those resistant to Oseltamivir and the newer drug, Marbofloxacin [7][8]. Market Potential - The Chinese flu medication market is projected to reach approximately 20 billion yuan, with Olanidavir expected to capture a significant share [19]. - The overall market for flu medications in China is nearing 20 billion yuan in 2023 and is anticipated to grow to 26.91 billion yuan by 2028 [18][19]. Future Plans - Zhongsheng Pharmaceutical aims to explore licensing opportunities for Olanidavir in international markets, particularly in the U.S. and Belt and Road countries, despite facing challenges in conducting large-scale clinical trials abroad [18]. - The company is also preparing for negotiations regarding national health insurance coverage for Olanidavir [18].

Core Insights - The article discusses the approval of a new influenza drug, Anglatavir, by China's drug regulatory authority, which is the first innovative drug to outperform the widely used Oseltamivir in head-to-head trials [1][3] - The drug targets the PB2 protein of the influenza virus and has been in development for 10 years, with expectations of capturing a market share of 2 billion yuan [1][10] Company Overview - Zhongsheng Pharmaceutical's subsidiary, Zhongsheng Ruichuang, is responsible for the development of Anglatavir, which has been a significant shift from traditional pharmaceutical practices to innovative drug development [2][8] - The company faced challenges during the development process, particularly after Johnson & Johnson's failure in clinical trials for a similar drug, VX-787, which raised doubts among investors [6][9] Market Context - The influenza drug market in China has evolved significantly, with Oseltamivir and the newer drug, Marbofloxacin, dominating the market [2][3] - The market for antiviral drugs in China is approaching 20 billion yuan, with projections indicating growth to 26.91 billion yuan by 2028 [9][10] Clinical Trial Results - Phase III clinical trial results showed that Anglatavir significantly reduced the time to symptom relief and viral load compared to Oseltamivir, indicating its potential effectiveness [3][4] - Anglatavir demonstrated superior efficacy against strains resistant to both Oseltamivir and Marbofloxacin, suggesting a strong competitive advantage [3][4] Future Prospects - The company plans to explore licensing opportunities for Anglatavir in international markets, particularly in the U.S. and Belt and Road countries, despite facing challenges in conducting large-scale clinical trials abroad [9][10] - The drug is currently approved for adults with uncomplicated influenza, and a pediatric formulation is in the pipeline, which could further expand its market reach [10]

Group 1: Market Performance - Major indices experienced a strong rebound, with the Shanghai Composite Index rising by 0.7%, Shenzhen Component Index by 1.24%, and ChiNext Index by 1.37% [2] - Over 4,200 stocks in the two markets saw gains, with a total trading volume of approximately 1.19 trillion yuan [2] Group 2: Digital Currency and Software Sector - The digital currency and software sectors led the market rally, with notable stocks like Lakala (300773.SZ) and Sifang Jingchuang (300468.SZ) hitting the daily limit with a 20% surge [2] - New Guodu (300130.SZ) rose over 14%, while Feitian Chengxin (300386.SZ) and Shenzhou Information (000555.SZ) also saw significant increases of 12.84% and 10%, respectively [2] Group 3: Autonomous Driving and Intelligent Connected Vehicles - Stocks related to autonomous driving and intelligent connected vehicles surged, with companies like Fulongma (603686.SH) and Jintour Environment (001230.SZ) hitting the daily limit [3] - A strategic cooperation agreement was signed between Xiaoma Zhixing and Guangzhou Public Transport Group, focusing on autonomous vehicle services [3] Group 4: Innovative Pharmaceuticals - The innovative pharmaceutical sector remains active, with companies like Sanofi Guojian (688336.SH) rising over 12% [4][3] - The sector is supported by policy backing, global competitiveness, and improving fundamentals, with a focus on "innovation + internationalization" [4] Group 5: Automotive Sector - The automotive sector showed strong performance, with Jinlong Automobile (600686.SH) and Dongfeng Co. (600006.SH) both increasing by 10% [5] - The launch of new models by XPeng and supportive government policies in Fujian province are contributing factors to the sector's growth [5] Group 6: Weak Sectors - The precious metals and food processing sectors experienced declines, with companies like Western Gold (601069.SH) and Laiyifen (603777.SH) seeing significant drops [5]

Group 1 - A total of 26 companies were investigated by institutions on May 26, with 20 companies specifically targeted by funds [1] - The most popular company among funds was Cankin Technology, which had 13 participating funds, followed by Greebo and Hars, each with 12 funds [1] - The companies investigated belong to various sectors, including electronics, machinery, basic chemicals, and pharmaceutical biology, with three stocks from each of these sectors being highlighted [1] Group 2 - Among the companies investigated, four had a total market capitalization exceeding 50 billion yuan, with BOE Technology Group being one of them, while ten companies had a market cap below 10 billion yuan [1] - In terms of market performance, eight stocks among the investigated companies saw an increase in the last five days, with Kailer Co., Zhongsheng Pharmaceutical, and Zhongchumei leading with increases of 21.62%, 7.52%, and 5.76% respectively [1] - Conversely, twelve stocks experienced declines, with Jiangnan Yifan, Tangyuan Electric, and Greebo showing the largest drops of 5.68%, 4.34%, and 3.89% respectively [1] Group 3 - The funds that participated in the investigations included significant net inflows, with Zhongsheng Pharmaceutical receiving a net inflow of 122 million yuan, the highest among the stocks [2] - Other companies with notable net inflows included Haida Group and Kailer Co., with net inflows of 36.68 million yuan and 11.77 million yuan respectively [2] - The table of companies investigated includes various details such as stock codes, latest closing prices, five-day price changes, and industry classifications [2][3]